A U.S. citizen who contracted Ebola while working in the Democratic Republic of Congo was admitted early Monday to the special isolation unit at Frankfurt University Hospital, German officials confirmed, marking the second transfer of an American Ebola patient to the country in recent months.
The patient arrived at the hospital at around 3 a.m. local time after being infected with the Bundibugyo variant of the Ebola virus while in Congo, according to hospital officials. The U.S. Centers for Disease Control and Prevention said on Friday that the individual, a citizen working for a humanitarian organization in the country, had tested positive for this strain of Ebola. Reports indicate the patient is a man in his 60s employed as a warehouse manager by the Christian relief group Samaritan’s Purse.
Timo Wolf, head of the hospital’s special isolation unit for highly infectious diseases, said the patient’s condition is currently stable, and that the transfer to Germany had proceeded without complications. He noted that Ebola patients are moved in specially equipped aircraft designed to prevent any exposure during transit, and that the isolation ward where the patient is now being cared for is structurally and organizationally separated from the rest of the hospital.
Germany’s Health Ministry stressed that the arrival of the patient poses no danger to the public or to other patients at the facility, since strict containment protocols govern every stage of treatment, from airlift to bedside care. Ebola spreads through direct contact with bodily fluids of an infected person, making rigorous isolation essential to preventing any secondary transmission once a patient reaches a hospital setting.
The Frankfurt admission is not the first time Germany has treated an Ebola patient evacuated from the outbreak zone. In June, another American who had contracted Ebola in Congo was discharged from Berlin’s Charité hospital after recovering. That earlier case, along with a French doctor who was isolated in France in late June after testing positive following his return from eastern Congo, underscores how the current Ebola outbreak has increasingly required international medical evacuations for aid workers and health professionals operating in the region.
The outbreak driving these transfers has grown rapidly. Congo’s public health institute reported on Monday that confirmed Ebola cases in the country had climbed to 1,926, with 702 deaths, as the epidemic spread into two additional provinces, Haut-Uele and Tshopo. Officials say 318 patients have recovered so far. Health experts have described the pace of the outbreak as unprecedented, noting that no previous Ebola epidemic has spread as quickly as the current one, even though the death toll remains far below the more than 11,000 lives lost during the West Africa Ebola epidemic of 2014 and 2015.
Part of the challenge is that the Bundibugyo strain now circulating in Congo has no licensed vaccine or approved treatment, unlike the more familiar Zaire strain, for which two vaccines already exist. In response, a clinical trial testing two experimental therapies, the monoclonal antibody MBP134 and the antiviral drug remdesivir, began in Congo on July 2. Separately, the University of Oxford has launched an early-stage human trial of a vaccine candidate targeting the Bundibugyo strain, using viral vector technology similar to that behind the Oxford-AstraZeneca COVID-19 vaccine, while the Serum Institute of India has already manufactured hundreds of thousands of doses in anticipation of wider approval.
For now, attention remains on the patient in Frankfurt, whose stable condition offers a measure of reassurance even as Ebola continues to spread across Congo. German health authorities say they are prepared to handle further Ebola cases should more aid workers require evacuation, relying on the same specialized isolation infrastructure that has now been used twice in a matter of months.
